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Background. We explored the long-term clinical outcomes including metastases-free survival and prostate cancer-speciﬁc survival
(PCSS) in patients with pathologic Gleason 8–10 disease after radical prostatectomy (RP). Methods. We report on 91 patients with
PCSS data with a median followup of 8.2 years after RP performed between 1988 and 1997. Cox regression and Kaplan-Meier
analysis were used to evaluate year of surgery, pathologic stage, and surgical margin status as predictors of PCSM. Results. Median
age was 65 years (IQR: 61–9), and median PSA was 9.7ng/ml (IQR: 6.1–13.4). Of all patients, 62 (68.9%) had stage T3 disease or
higher,and48(52.7%)hadapositivesurgicalmargin.Onmultivariateanalysis,noneofthepredictorswerestatisticallysigniﬁcant.
Of all patients, the predicted 10-year BCR-free survival, mets-free survival, and PCSS were 59% (CI: 53%–65%), 88% (CI: 84%–
92%), and 94% (CI: 91%–97%), respectively. Conclusions. We have demonstrated that cancer control is durable even 10 years after
RP in those with pathologic Gleason 8–10 disease. Although 40% will succumb to BCR, only 6% of patients died of their disease.
These results support the use of RP for patients with high-risk localized prostate cancer.
1.Introduction
Since the advent of widespread prostate-speciﬁc antigen
(PSA) testing in the late 1980s and early 1990s, PC detection
has increased with a concomitant downward-shift in stage
[1, 2]. In addition to PSA, the introduction of the anatomic
radical retropubic prostatectomy (RP) [3, 4], breakthroughs
in radiotherapy delivery [5], and systemic chemotherapeutic
agents [6] have resulted in a 30% mortality reduction
[7]. Despite the stage shift and treatment improvements,
15% of contemporary patients will present with high-
risk localized prostate cancer [8]. Contemporary high-risk
disease is generally deﬁned by high Gleason score rather than
elevated PSA or advance stage due PSA testing and digital
rectal examination [8, 9]. Unfortunately, 50% of patients
with high-risk disease will succumb to biochemical failure
within 10 years [10, 11].
Although there are no randomized trials that support the
use of RP for patients with high-risk disease, recent retro-
spective studies lend credence to the use of RP as an eﬀective
therapy for this group of patients [12, 13]. The renewed
interest is based on multiple beneﬁts of surgery. First, it
provides excellent local control. Second, it better deﬁnes
the extent of disease than biopsy alone [14]. Third, with
prostate removal, PSA failures can be more easily detected.
Fourth, radiation can be given in the adjuvant or salvage set-
ting whereas surgery after radiation is associated with high
complication rates [15].
In that context, we hypothesized that patients with path-
ologic Gleason 8–10 disease may have better long-term
clinical outcomes after RP than previously thought. Thus we
explored the long-term clinical outcomes including metasta-
ses-free survival and prostate cancer-speciﬁc survival (PCSS)
in these high-risk patients after RP.2 Advances in Urology
2.MaterialsandMethods
We retrospectively analyzed charts of patients who under-
went radical prostatectomy (RP) between 1988 and 1997
at Virginia Mason Medical Center (VMMC). No patient
received neoadjuvant therapy. One of the authors (R. Gib-
bons)loggedclinicalandpathologicaldataintoaprospective
database from 1988 to 1999. After 1999, the records were
maintained electronically with institutional review board
(IRB) approval. PSA testing began in 1988 at VMMC. All
patients were operated between 1988 and 1997. We subse-
lectedfora cohortof 91 patients thathad pathologic Gleason
8 disease or higher and had postoperative PSA data available.
Of all patients, 66 (72.5%) underwent radical retropubic
prostatectomy (RRP) and 25 (27.5%) underwent radical
perineal prostatectomy (RPP). All specimens were evaluated
by VMMC pathologists. Specimens were processed as half
mount specimens and serially sectioned at 5mm intervals.
Alternate 5mm sections were ﬁxed in formalin and were
paraﬃn embedded. From 1988 to 1992 pathological tumor
stage was recorded according to the Whitmore-Jewett classi-
ﬁcation and later converted to the 1992 AJCC staging guide-
lines [16, 17] From 1992 to 1997 the 1992 AJCC staging
system was used for clinical and pathological staging.
From 1992 to 1997 tumors were routinely classiﬁed ac-
cording to the Gleason grading system [18]. Before 1992
tumor grade was recorded as well diﬀerentiated (I), mod-
erately diﬀerentiated (II), and poorly diﬀerentiated (III). To
recode these data we followed the paradigm outlined by
Roehl et al., in which well-diﬀerentiated tumors are classiﬁed
as Gleason sum 3, moderately diﬀerentiated tumors are
assigned Gleason sum 6, and poorly diﬀerentiated tumors
are assigned Gleason sum 9 [19]. Positive surgical margins
were recorded as presence of cancer cells against the inked
resection margin.
Serum PSA testing was initiated at VMMC in 1988. Since
that time patients were followed at least quarterly for 2
years, then at least biannually for 2 years, and then at least
annually. Biochemical recurrence was deﬁned as PSA
greater than 0.1ng/mL. Metastases were diagnosed based on
technetium-99m-basedbonescintigraphicstudies,andcom-
puted tomography cross-sectional imaging was used in
equivocal cases. Adjuvant or salvage hormonal and/or ra-
diotherapy were delivered according to individual surgeon
preference. Adjuvant therapy was deﬁned as adjunctive
radiotherapy in the absence of PSA recurrence (PSA <
0.1ng/mL) given within 6 months of surgery. Neoadjuvant
hormonal therapy was deﬁned as hormone delivery prior to
surgery. Cause of death was ascertained according to detailed
chart review or was obtained from the VMMC cancer reg-
istry.ThecancerregistryuseslinkswiththeWashingtonState
Death Certiﬁcate Oﬃce. PC must be the ﬁrst listed cause of
death on the certiﬁcate for a patient to be classiﬁed as having
died of PC.
Prostate cancer-speciﬁc mortality was analyzed with uni-
variateandmultivariateCoxregressionmodelsbasedonpre-
operative and operative factors. Predictors included year of
surgery, 1992 AJCC pathological stage, and surgical margin
status.
Table 1: Demographics and pathologic and clinical outcomes.
Characteristic No. (IQR)
Median followup in years 8.2 (4.5–12.5)
Median age in years 65 (61–69)
Median pre-op PSA 9.7 (6.1–13.4)
Pathologic tumor volume 5.3 (3.0–12.0)
Pathologic Gleason sum No. (%)
Gleason 8 68 (74.7)
Gleason 9 22 (24.2)




Positive margins 48 (52.7)





Adjuvant radiation 10 (11.0)
Salvage radiation 10 (11.0)
Neoadjuvant ADT 9 (9.9)
Salvage ADT 19 (20.9)
Biochemical recurrence 33 (36.3)
Metastatic disease 8(8.8)
PCSM 9 (9.9)
Total no. patients 91 (100)
ADT: androgen deprivation therapy.
Actuarial analyses addressed the outcomes of PSA recur-
rence, distant recurrence, PCSS, and overall survival. In
analyses of PCSS, patients without evidence of progression
were censored at the time of last followup. A biochemical
recurrence event for the purposes of Kaplan-Meier analysis
was deﬁned as a PSA of 0.1ng/mL or the delivery of radio-
therapy or hormonal therapy after later than 6 months after
surgery. Kaplan-All statistical tests and ﬁgures were per-
formed with S-PSS (2009) and statistical signiﬁcance was set
at 0.05.
Patients who died of other causes were censored at
time of death. PSA recurrence-free data were censored if
radiotherapy and/or hormonal therapy were delivered before
PSA recurrence.
3. Results
Clinical and pathologic characteristics are shown in Table 1.
The median followup was 8.2 years (interquartile range
[IQR]: 4.5–12.5 years). The median age of the 91 person
cohort was 65 years (IQR: 61–69 years) and the median
PSA was 9.7ng/mL (IQR: 6.1–13.4). At time of pathological
analysis after RP, 62 (68.9%) had stage T3 disease or higher,
23 (25.3%) had pathologic Gleason 9 or higher, and 48
(52.7%) had a positive surgical margin.Advances in Urology 3
Table 2: Binary logistic regression for prostate cancer-speciﬁc mortality.
Characteristics Univariate hazard ratio (95% CI) (P value) Multivariate hazard ratio (95% CI) (P value)
Pre-op PSA 1.038 (0.970–1.112) 0.278 1.042 (0.953–1.139) 0.366
Gleason (8 versus 9–10) 0.830 (0.160–4.312) 0.825 1.087 (0.106–11.146) 0.944
Stage (pT3/4 versus pT2) 4.000 (0.476–33.645) 0.202 0.627 (0.032–12.429) 0.759
Margin status 1.905 (0.446–8.136) 0.384 4.943 (0.342–71.440) 0.241
XRT received 1.912 (0.433–8.442) 0.392 3.529 (0.356–34.987) 0.281
ADT received 3.207 (0.790–13.007) 0.103 0.703 (0.050–9.948) 0.795
Node status 1.257 (0.127–12.419) 0.845 2.127 (0.059–77.249) 0.680
XRT = adjuvant or salvage radiotherapy; ADT: hormone use for relapse.
Table 3: Kaplan-Meier actuarial estimates of BCR-free survival, metastases-free survival, overall survival, and prostate cancer speciﬁc
survival (PCSS).
Cohort Overall cohort pT2/margin − pT3 or margin + pT3 & margin +
No at risk/5-year BCR-free survival (CI) 90/0.69 (0.064–0.74) 22/0.84 (0.76–0.90) 25/0.65 (0.55–0.75) 42/0.64 (0.56–0.68)
No at risk/5-year mets-free survival (CI) 90/0.94 (0.91–0.97) 22/1.00 (1.00–1.00) 25/0.96 (0.92–1.00) 42/0.89 (0.84–0.94)
No at risk/5-year overall survival (CI) 90/0.96 (0.94–0.98) 22/1.00 (1.00–1.00) 25/1.00 (1.00–1.00) 42/0.92 (0.88–0.96)
No at risk/5-year PCSS (CI) 90/0.97 (0.95–0.99) 22/1.00 (1.00-1.00) 25/1.00 (1.00-1.00) 42/0.95 (0.91–0.99)
No at risk/10-year BCR-free survival (CI) 47/0.59 (0.53–0.65) 13/0.77 (0.66–0.88) 13/0.65 (0.55–0.75) 21/0.47 (0.38–0.56)
No at risk/10-year mets-free survival (CI) 61/0.88 (0.84–0.92) 16/1.00 (1.00-1.00) 19/0.96 (0.92–1.00) 26/0.77 (0.69–0.85)
No at risk/10-year overall survival (CI) 65/0.84 (0.79–0.89) 16/0.85 (0.75–0.95) 20/0.83 (0.74–0.92) 29/0.85 (0.79–0.91)
No at risk/10-year PCSS (CI) 65/0.94 (0.91–0.97) 16/1.00 (1.00-1.00) 20/0.88 (0.80–0.96) 29/0.95 (0.91–0.99)
No at risk/15-year BCR-free survival (CI) 29/0.52 (0.45–0.59) 8/0.77 (0.66–0.88) 9/0.45 (0.31–0.59) 12/0.47 (0.38–0.56)
No at risk/15-year mets-free survival (CI) 37/0.88 (0.84–0.92) 9/1.00 (1.00-1.00) 12/0.96 (0.92–1.00) 16/0.77 (0.69–0.85)
No at risk/15-year overall survival (CI) 40/0.69 (0.62–0.76) 9/0.85 (0.75–0.95) 12/0.74 (0.62–0.86) 19/0.59 (0.48–0.70)
No at risk/15-year PCSS (CI) 40/0.80 (0.73–0.87) 9/1.00 (1.00-1.00) 12/0.78 (0.66–0.90) 19/0.73 (0.62–0.84)
Table 2 showstheunivariateandmultivariateCoxregres-
sion model predicting prostate cancer-speciﬁc mortality. On
both univariate and multivariate analysis, none of predictors
remained statistically signiﬁcant (P>0.05).
Figure 1 graphically displays Kaplan-Meier estimates of
BCR (a), metastases (b), overall survival (c), and PCSS (d)
stratiﬁed by pathologic stage and surgical margin status.
There was a trend for mean times to BCR (P = 0.081),
and metastatic disease (P = 0.060), to be diﬀerent between
pT2/margin negative patients and pT3/margin positive
patients.
Table 3 provides Kaplan-Meier actuarial estimates for
time to BCR, metastases, overall survival and PCSS. Of all
patients, the predicted 10-year BCR-free survival, mets-free
survival, and PCSS were 59% (CI: 53%–65%), 88% (CI:
84%–92%), and 94% (CI: 91%–97%), respectively. Specif-
ically, the predicted 10-year BCR-free rate was signiﬁcantly
better in those with organ-conﬁned margin negative disease
(pT2) than in those with locally advanced (pT3) margin
positive disease (77% (CI: 66%–88%) versus 47%(CI: 38%–
56%)). The predicted 15-year PCSS was signiﬁcantly better
in those with organ-conﬁned margin negative disease (pT2)
than in those with locally advanced (pT3) margin positive
disease(100%(CI:100%-100%)versus73%(CI:62%–84%)).
4. Discussion
We have demonstrated in a cohort with a median followup
time of 8.2 years that cancer control is durable even 10 years
after RP in those with pathologic high-grade disease. Al-
though, 41% of patients developed BCR by 10 years, only
12% of patients in this extremely high-risk group progressed
to distant metastases, and just 6% of patients actually died of
their disease (Table 3).
When put into context, 59% of all patients with patho-
logic Gleason 8 disease or higher and 47% of patients with
pathologicGleason8diseaseorhigher,pT3stageandmargin
positive disease were cured of their disease (no BCR within
10yr) with primary RP (Table 3). However, cure was not
achievedsolelywithsurgery.Ofallpatients,11receivedsolely
postoperative radiotherapy, 10 received long-term hormonal
therapy, and 9 received both postoperative radiotherapy and
long-term hormonal therapy. Clearly, this is a group of pa-
tients that will require multimodal therapy to achieve robust
durable outcomes.
Our 10-year actuarial disease-speciﬁc mortality estimate
(6%) was similar to other long-term RP series, including the
UCLA group (8%) [20] and Hull et al. (2.4%) [21], and
compares favorably with reports that have examined locally
advanced disease speciﬁcally [12, 22].
It is intriguing that the classical predictors of outcome
such as pathological stage and surgical margin status did
not reach statistical signiﬁcance in our multivariate analysis.
However, the multivariate eﬀect of these variables on PCSS
was not assessed in most other long-term outcome series
except that of Stephenson et al. [23]. However, stage was a
signiﬁcant predictor on multivariate analyses of BCR after4 Advances in Urology
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Figure 1: Kaplan-Meier estimates of BCR (a), distant recurrence (b), overall survival (c), and disease-speciﬁc survival (d) according to stage
and surgical margin status.
RP in other series with long-term followup [19, 21]a sw a s
surgical margin status [21]. Thus, the positive predictor
status of these classic variables with regard to BCR, but their
inability to predict long-term PCSM suggest that they may
notbeimportantwithregardtolong-termoncologiccontrol.
This assumption will require further study in other long-
term followup RP series.
The results of our study must be interpreted within the
strengths and limitations of our study. First, our data derive
from a single center over 20 years, and involve multiple
surgeons. Thus, patient selection and surgical technique cer-
tainly diﬀered and possibly may have introduced variation
in outcome [24]. Moreover, patients underwent two surgical
techniques, namely, RPP and RRP, which may have aﬀected
outcome. However, the literature suggests that there is
no diﬀerence between RPP and RRP oncologic outcomes
[25]. Second, we recognize that there is no centralized
pathologic review and that therefore contemporary Gleason
scores may well be ascribed a higher value [14]. However,
all pathology was read at a single tertiary referral centerAdvances in Urology 5
with a high level of GU pathology expertise. Moreover, we
relied upon the original pathology report from VMMC
to establish the histological diﬀerentiation. Gleason scores
were not routinely recorded before 1992, and therefore, we
relied upon the paradigm used by Roehl to assign Gleason
scores to patients undergoing surgery before 1992 [19]. Fi-
nally, postoperative use of radiation and androgen depri-
vation therapy were given at the discretion of the treating
physician and may have introduced substantial bias into the
interpretation of the results.
5. Conclusions
In summary, we have demonstrated in a cohort with a me-
dian followup time of 8.2 years that cancer control is durable
even 10 years after RP in those with pathologic Gleason 8–
10 disease. Although, 41% of patients developed BCR by 10
years,only12%ofpatientsinthishigh-riskgroupprogressed
to metastases, and just 10% of patients died of their disease.
Taken together, these long-term oncologic results support
the use of RP for patients with high-risk localized prostate
cancer.
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